Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
uniQure logo — Transforming the lives of patients through gene therapy

uniQure

Transforming the lives of patients through gene therapy

Founded 1998 The Netherlands The Netherlands 323 employees IPO Total: $1.12B Biotechnology, Pharmaceutical

General Information

Company Name uniQure
Founded Year 1998
Location The Netherlands The Netherlands
Employees 323
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Business Model B2B, B2C, B2B2C
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with uniQure. To contact uniQure, visit uniqure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does uniQure compare?

A PDF of uniQure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting uniQure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About uniQure

uniQure, founded in 1998, is at the forefront of gene therapy innovation, with a commitment to transforming the lives of patients through single treatments that hold potentially curative outcomes. The company leverages a modular and validated technology platform, which fuels its rapid advancement of proprietary and partnered gene therapies aimed at alleviating severe genetic diseases.

Recently, uniQure secured a substantial $175.00 million post-IPO equity investment, led by Hercules Capital on 01 September 2025. This funding underscores the confidence investors have in the company's technology and pipeline, propelling its strategy to lead advancements in gene therapy. With its promising trajectory and strategic backing, uniQure stands as a compelling entity for investors interested in high-impact healthcare innovations.

Business keywords: Gene Therapy, Genetic Diseases, Therapeutic Development, Modular Technology Platform, Huntington's Disease, AAV (Adeno-Associated Virus), ALS (Amyotrophic Lateral Sclerosis), Epilepsy Treatment, Fabry Disease, Proprietary Therapies, Partnerships in Healthcare, Innovative Medical Treatments, Curative Treatments

Services & Products

Innovative Cures Development
Gene Therapy Research
Clinical Trials Execution
Patient Care and Support
Regulatory Compliance

Target Customers

Patients and Families Healthcare Providers Investors Pharmaceutical Partners Regulatory Bodies

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $175.00M 1
Hercules Capital
Hercules Capital
01 Sep 2025
Post-IPO Equity $75.00M -
01 Jan 2025
Post-IPO Equity $150.00M -
01 Mar 2020
Post-IPO Equity $225.00M -
01 Sep 2019
Post-IPO Equity $147.49M -
01 May 2018
Post-IPO Equity $91.25M -
01 Oct 2017
Post-IPO Equity $89.00M -
01 Apr 2015
Post-IPO Debt $20.00M -
01 Jul 2014
IPO $88.50M -
01 Mar 2014
Growth Equity VC $58.00M 3
Forbion Chiesi Ventures Coller Capital
Forbion, Chiesi Ventures +1
01 Jul 2013

View All 12 Funding Rounds

Latest News

View All
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say  — Cnbc
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say 
Cnbc Aug 25, 2026
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency — Cnbc
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
Cnbc Jun 17, 2026

uniQure Alternatives & Competitors

View All Alternatives
uniQure vs
Bloomsbury Genetic Therapies
Bloomsbury Genetic Therapies United Kingdom

Dedicated to delivering the promise of gene therapy

Seed
2 employees
Biopharma, Biotechnology
uniQure vs
Adverum Biotechnologies
Adverum Biotechnologies United States

We are on a global mission to establish gene therapy as a new standard of care for the leading cause...

Acquired
133 employees
Biotechnology, Health and Wellness
uniQure vs
bluebird bio
bluebird bio United States

Pursuing curative gene therapies to give patients and their families more bluebird days.

IPO
548 employees
Biotechnology, Health Care
View all alternatives

FAQ About uniQure

Transforming the lives of patients through gene therapy
uniQure was founded in 1998.
uniQure is headquartered in The Netherlands.
uniQure operates in Biotechnology and Pharmaceutical. Its work centres on Gene Therapy, Genetic Diseases, Therapeutic Development and Modular Technology Platform. Its customers include Patients and Families, Healthcare Providers and Investors.
uniQure has a B2B, B2C and B2B2C business model. Its revenue comes from Licensing, Performance Based and Product Sales.
uniQure has approximately 323 employees.
uniQure has completed 12 funding rounds, raising a total of $1.12B. The latest funding stage is IPO.
uniQure offers: Innovative Cures Development, Gene Therapy Research, Clinical Trials Execution, Patient Care and Support, Regulatory Compliance.
Top alternatives and competitors to uniQure include Bloomsbury Genetic Therapies, Adverum Biotechnologies, bluebird bio, AusperBio, Ultragenyx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
uniQure and Bloomsbury Genetic Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for uniQure, https://bouncewatch.com/company/uniqure, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout